title: [POPP syndrome: Psoriatic onychopachydermoperiostitis].
abstract: Psoriatic onychopachydermoperiostitis (POPP) syndrome characterizes a clinical variant of psoriatic arthritis originally described by Fournie et al in 1989. Both great toes are generally affected presenting with nail changes, painful swelling of the soft tissue close to the distal phalanx as well as specific radiologic changes such as periosteal reaction and bone erosions of the distal phalanges. Joint involvement is characteristically absent and classic psoriatic lesions may be associated. Painful symptoms may lead to severe functional and quality of life impairment. Traditional systemic treatment is generally frustrating. Here we report a female patient presenting POPP syndrome refractory to traditional systemic treatments and adalimumab, further presenting a favorable response to treatment with etanercept.
authors.affiliation: Departamento de Dermatologia do Hospital das Clínicas da Universidade de São Paulo, Brazil.
authors.forename: Ricardo
authors.initials: R
authors.lastname: Romiti
authors.forename: Denise
authors.initials: D
authors.lastname: Santos
authors.forename: Jozélio
authors.initials: J
authors.lastname: Carvalho
authors.forename: Marcelo
authors.initials: M
authors.lastname: Arnone
authors.forename: Maria Denise F
authors.initials: MD
authors.lastname: Takahashi
mesh_terms: D015535:Arthritis, Psoriatic / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D001688:Biological Products / Q000627:therapeutic use; D000068800:Etanercept; D005260:Female; D005533:Foot Dermatoses / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D054039:Onycholysis / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D013577:Syndrome; D014034:Toes / Q000473:pathology
chemical_list: D001688:Biological Products; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept